Medtronic in.pact drug-eluting balloon studies show significant benefit of novel medical device in treating narrowed arteries

Medtronic, 05/18/2012

Adding to the growing body of evidence on a novel interventional cardiovascular device, physicians presented today at EuroPCR 2012 the results of two multicenter, randomized controlled trials, the BELLO and PACIFIER studies, each one showing statistically significant advantages of using an IN.PACT drug–eluting balloon from Medtronic, Inc. (NYSE: MDT) over a corresponding conventional treatment for coronary and peripheral artery disease, respectively.

Go to Abstract Print Article Summary